Analyst Price Targets — ADC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 1:27 pm | — | UBS | $91.00 | $81.06 | TheFly | Agree Realty price target raised to $91 from $82 at UBS |
| February 12, 2026 2:59 pm | Brad Heffern | RBC Capital | $81.00 | $76.72 | TheFly | Agree Realty price target raised to $81 from $79 at RBC Capital |
| February 11, 2026 11:43 am | — | Stifel Nicolaus | $84.50 | $76.51 | TheFly | Agree Realty price target raised to $84.50 from $83.50 at Stifel |
| December 17, 2025 11:59 am | — | Mizuho Securities | $75.00 | $71.06 | TheFly | Agree Realty price target lowered to $75 from $77 at Mizuho |
| December 15, 2025 1:25 pm | — | Evercore ISI | $83.00 | $72.24 | TheFly | Agree Realty price target lowered to $83 from $85 at Evercore ISI |
| December 3, 2025 10:44 am | — | Barclays | $78.00 | $74.15 | TheFly | Agree Realty price target raised to $78 from $77 at Barclays |
| November 25, 2025 7:50 pm | John Kilichowski | Wells Fargo | $83.00 | $75.12 | TheFly | Agree Realty price target raised to $83 from $81 at Wells Fargo |
| November 25, 2025 5:25 pm | Simon Yarmak | Stifel Nicolaus | $83.50 | $75.10 | StreetInsider | Agree Realty (ADC) PT Raised to $83.50 at Stifel |
| October 24, 2025 1:10 pm | Ki Bin Kim | Truist Financial | $82.00 | $75.14 | TheFly | Agree Realty price target lowered to $82 from $84 at Truist |
| October 24, 2025 12:22 pm | Upal Rana | KeyBanc | $82.00 | $75.14 | StreetInsider | Agree Realty (ADC) PT Raised to $82 at KeyBanc; 'Investment Output Accelerating' |
Latest News for ADC
Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
High yields often hide trouble, and blue chips can still be overpriced. The best REITs are often quality names facing temporary issues. These REITs may offer yield and upside today.
Ingelheim, Germany and Shanghai , China /Cambridge, Mass. – 15 April , 202 6 – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-cell engager, with…
INCHEON, Korea--(BUSINESS WIRE)-- #ADC--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis's first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an…
U.S. equity markets extended their rebound this week as investors welcomed tentative progress toward de-escalation in the Middle East following several days of dramatic threats of significant escalation. The fragile pause in hostilities temporarily eased fears of a prolonged disruption to global energy supplies and fueled a sharp retreat in oil prices after a surge to four-year highs. Markets also found support from…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.